Bildkälla: Stockfoto

Xspray Pharma: Q1 comment - Redeye

Redeye reiterates its Base Case of SEK 170 following today's release of the report for the first quarter of 2021. We provide a brief comment on the financials and highlight the most important events during the period.

Redeye reiterates its Base Case of SEK 170 following today's release of the report for the first quarter of 2021. We provide a brief comment on the financials and highlight the most important events during the period.
Börsvärldens nyhetsbrev
ANNONSER